Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINT: AZD8931 plus anastrozole versus anastrozole alone in hormone receptor-positive advanced breast cancer
2009-012934-63Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing AZD8931 + anastrozole with Placebo + anastrozole (2 arms). Primary endpoint: Progression-free survival. Started Sep 2009; status: terminated.
02
Drugs
sapitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-012934-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012934-63.